Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Triple Negative Breast Neoplasms|TNBC - Triple-Negative Breast Cancer|Triple-negative Breast Carcinoma
Interventions: DRUG: Durvalumab|BIOLOGICAL: Neoantigen DNA vaccine|DEVICE: TDS-IM system (Inchor Medical Systems)|PROCEDURE: Peripheral blood draw
Sponsor: Washington University School of Medicine
Collaborators: MedImmune LLC|National Cancer Institute (NCI)|National Institutes of Health (NIH)